The company also offers medical devices in the form of intraocular lenses. Valeant produces drugs, dietary supplements, cosmetics and medical devices. Its plants comply with good manufacturing ...

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures, and markets a range of branded and generic pharmaceuticals, over-the ...

The company also offers medical devices in the form of intraocular lenses. Valeant produces drugs, dietary supplements, cosmetics and medical devices. Its plants comply with good manufacturing ...

MONTREAL - Explosive, unproven allegations against Valeant Pharmaceuticals have caught the eye of a Canadian regulator and raised serious questions about the company's business structure — even ...

And on Wednesday, when company executives and board member, billionaire hedge fund manager Bill Ackman, went to the U.S. Senate to testify about Valeant's pricing practices, they were asked a ...

And based on this statement Valeant just put out, the company is going to have a lot of explaining to do in terms of the language it has used to describe "growth." Here's the part of the statement ...

Valeant Pharmaceuticals is seeking to strengthen its cosmetics business with an agreement to buy Solta Medical for about US$250 million. The Montreal, Canada-based pharma - which also has ...

The company's new CEO, Howard Schiller, is slated to testify before Congress about Valeant's drug pricing practices next week, along with Martin Shkreli. Written by Linette Lopez Follow BI Video ...

Canada-based Valeant Pharmaceuticals announced on August 20 that it had entered into a definitive agreement to buy Sprout Pharmaceuticals for $1bn, with the opportunity for Sprout to enjoy a share of ...

The FDA has finally approved Valeant’s eye drug Vyzulta after the company finally satisfied the regulator’s concerns over its manufacturing facility in Florida. The Quebec-based company’s ...

GSK will also gain the rights to Valeant's back-up compounds that target potassium channels. Valeant receives an upfront payment of $125 million, and will share up to 50% of net profits on ...